Background Pulmonary arterial hypertension is characterized by pulmonary vascular
remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone …

Background Pulmonary arterial hypertension is a progressive disease involving proliferative
remodeling of the pulmonary vessels. Despite therapeutic advances, the disease-associated …

Background In participants with pulmonary arterial hypertension, 24 weeks of sotatercept
resulted in a significantly greater reduction from baseline in pulmonary vascular resistance …

Background In the phase 3 STELLAR trial, sotatercept, an investigational first-in-class activin
signalling inhibitor, demonstrated beneficial effects on 6-min walk distance and additional …

Major advances in pulmonary arterial hypertension, pulmonary hypertension (PH)
associated with lung disease, and chronic thromboembolic PH cast new light on the …

Pulmonary arterial hypertension (PAH) is a rare disease associated with abnormally
elevated pulmonary pressures and right heart failure resulting in high morbidity and …

Background Despite advances in the management of pulmonary arterial hypertension
(PAH), the mortality rate remains excessive. Long-term efficacy evaluations are needed to …

Sitaxsentan may benefit patients with pulmonary arterial hypertension by blocking the
vasoconstrictor effects of endothelin-A while maintaining the vasodilator/clearance functions …

Sotatercept is an activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein that improves
cardiopulmonary function in patients with pulmonary arterial hypertension (PAH) by …

Background Some endothelin receptor antagonists (ERAs) are associated with liver function
test (LFT) result abnormalities. However, ambrisentan has an incidence of serum …